Single dose of ketotifen fumarate .025% vs 2 weeks of cromolyn sodium 4% for allergic conjunctivitis
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
This single-masked, contralateral-eye, active-controlled allergen-challenge study compared ketotifen fumarate .025% and cromolyn sodium 4% ophthalmic solutions in the prevention of ocular itching, tearing, and redness induced by allergen challenge. After a confirmatory conjunctival provocation test (CPT), 56 patients randomly received masked study medication (placebo in one eye, cromolyn in the other eye) four times daily for 2 weeks. At visit 3, patients received one drop of ketotifen in the eye previously treated with placebo and cromolyn in the other eye. Ocular comfort was assessed 30 seconds postinstillation, and a CPT was conducted 15 minutes and 4 hours postinstillation to evaluate ocular itching, tearing, and redness. Forty-seven patients were analyzed for efficacy. At the 15-minute and 4-hour challenges, ketotifen was superior to cromolyn in preventing itching (P<.001) at all assessments and redness (ciliary, conjunctival, and episcleral) (P≤.001 ) at most assessments. Tearing scores were higher in cromolyn-treated eyes than in ketotifen-treated eyes. Patients reported greater comfort in the ketotifentreated than in the cromolyn-treated eye (P= .066). The most common adverse event was burning/stinging with cromolyn. A single dose of ketotifen was superior to a 2-week four-times-daily regimen of cromolyn in alleviating symptoms of allergic conjunctivitis in the conjunctival allergen-challenge model.
- Weeke ER. Epidemiology of hay fever and perennial allergic rhinitis.Monogr Allergy. 1987;21:1–20.
- Abelson, MB, George MA, Garafalo C. Differential diagnosis of ocular disorders.Ann Allergy. 1993;70:95–113.
- Allansmith MR, Greiner JV, Baird RS. Number of inflammatory cells in normal conjunctiva.Am J Ophthalmol. 1978;86:250–259.
- Allansmith MR. Immunology of the eye. In: Allansmith MR, ed.The Eye and Immunology. St. Louis: CV Mosby; 1982:99–115.
- Abelson MB, Chapin MJ. Current and future topical treatments for ocular allergy.Compr Ophthalmol Update. 2000;1:303–320.
- Collum LMT, Kilmartin DJ. Acute allergic conjunctivitis. In: Abelson MB, ed.Allergic Diseases of the Eye. Philadelphia: WB Saunders; 2000:120–127.
- Investigator’s Brochure—Ketotifen Fumarate Eye Drops. 5th ed. Duluth, Ga: Novartis Ophthalmics; November 2001.
- Grant SM, Goa KL, Fitton A, et al. Ketotifen: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma and allergic disorders.Drugs. 1990;40:412–448. CrossRef
- Nabe M, Miyagawa H, Agrawal DK, et al. The effect of ketotifen on eosinophils as measured at LTC4 release and by chemotaxis.Allergy Proc. 1991;12:267–271. CrossRef
- Abelson MB, Chambers WA, Smith LM. Conjunctival allergen challenge—a clinical approach to studying allergic conjunctivitis.Ophthalmology. 1990;108:84–88.
- Allansmith MR, Ross RN. Ocular allergy and mast cell stabilizers.Surv Ophthalmol. 1986;30: 229–244. CrossRef
- Abelson MB, George MA, Smith LM. Evaluation of.05% levocabastine versus 4% sodium cromolyn in the allergen challenge model.Ophthalmology. 1995;102:310–316.
- Single dose of ketotifen fumarate .025% vs 2 weeks of cromolyn sodium 4% for allergic conjunctivitis
Advances in Therapy
Volume 19, Issue 4 , pp 185-193
- Cover Date
- Print ISSN
- Online ISSN
- Springer Healthcare Communications
- Additional Links
- allergic conjunctivitis
- clinical trial
- Industry Sectors
- Author Affiliations
- 1. Schepens Eye Research Institute and Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts
- 2. Department of Ophthalmology and Neurology, Boston University School of Medicine, Boston, Massachusetts
- 3. Novartis Ophthalmics, Inc., 11695 Johns Creek Parkway, 30097, Duluth, GA